AtaiBeckley Beats: Lilly Takes the Upside
AtaiBeckley delivered a 17.9% EPS beat, its first in at least four quarters, at the same moment Eli Lilly's $6.75 acquisition locked the ceiling on shareholder upside. At $7.25, the $0.50 premium abov
AtaiBeckley Beats Estimates as Lilly Deal Caps Upside
NEW YORK, August 14 —
AtaiBeckley Inc. (ATAI) posted its first earnings beat in at least four quarters ($-0.09 EPS against a $-0.112 consensus) precisely as Eli Lilly's $6.75 acquisition transferred that upside to the acquirer. Deutsche Bank downgraded on deal terms, not fundamentals. Shares at $7.25, $0.50 above the cash floor, price the contingent value right at something Wall Street won't credit.
- Lilly's deal: $6.75 cash per share plus a CVR, valuing AtaiBeckley at $2.8 billion.
- First earnings beat in four quarters: EPS of $-0.09 versus a $-0.112 consensus, a 17.9% positive surprise.
- Shares trade at $7.25, $0.50 above the acquisition price; the FactSet consensus target is $8.83.
The Beat That Bought Nothing
AtaiBeckley develops mental health treatments with one of the broader pre-revenue clinical pipelines: BPL-003, an intranasal mebufotenin formulation in Phase 2a and 2b for treatment-resistant depression and alcohol use disorder; an oral MDMA analog for social anxiety; and a DMT film alongside a pro-cognitive neuromodulator for schizophrenia-related impairment. The company has 99 employees, no commercial products, and $230 million in cash with zero debt. After three consecutive misses, including a $-1.73 EPS print against a $-0.112 estimate, the 17.9% positive surprise signaled a real inflection, the kind an acquirer's valuation model prices even when conventional metrics can't. Under the Lilly deal, that value now belongs to Lilly.
Three Executives Who Sold Too Soon
The insider sales provide an ironic footnote. Robert Hershberg sold 100,000 shares at $4.96 on July 7, generating $496,000; COO Gerd Kochendoerfer sold 50,000 shares at $5.00 on June 26 for $250,000; CMO Kevin James Craig sold 42,579 shares at $4.51 on June 25 for $192,031. All three settled between $1.75 and $2.24 per share below the deal price Lilly later agreed to pay. The timing does not imply wrongdoing, as executives sell for personal reasons, but the gap between those exit prices and the acquisition price suggests the deal terms surprised even those closest to the pipeline's development.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ATAI | $2.7B | n/a | +86.9% |
| GHRS | $2.0B | n/a | +120.4% |
| CMPS | $1.8B | n/a | +207.6% |
| HELP | $697M | n/a | +62.2% |
| IXHL | $38M | n/a | -72.3% |
| ABSI | $1.6B | n/a | +222.9% |
CVR Value Depends on Milestones, Not Operations
The $0.50 gap between the trading price and the cash floor represents the market's current CVR estimate: a bet on clinical milestones AtaiBeckley has not yet reached. Deutsche Bank's cut from a $12 to an $8 target, driven by deal structure rather than pipeline concern, endorsed the ceiling; upside beyond $6.75 is contingent on milestones, not guaranteed by operations. The FactSet consensus target of $8.83 suggests some analysts assign more CVR value than the current premium reflects. Ten DEFA14A proxy supplements filed July 16 show the merger process is active; those milestone terms will determine whether the CVR converts. Run the free AtaiBeckley Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What did AtaiBeckley report for earnings?
AtaiBeckley reported EPS of $-0.09 against a consensus estimate of $-0.112, a 17.9% positive surprise. It was the company's first earnings beat in at least four quarters, following three consecutive misses that included a $-1.73 EPS print against a $-0.112 estimate in a prior quarter.
What is Eli Lilly paying for AtaiBeckley?
Eli Lilly agreed to pay $6.75 in cash per share plus a contingent value right, valuing AtaiBeckley at $2.8 billion. Shares were trading at $7.25 at the time of publication, $0.50 above the acquisition price, with that premium representing the market's current estimate of the CVR.
What is the AtaiBeckley CVR worth?
The CVR value depends on clinical milestones AtaiBeckley has not yet reached and is not guaranteed by operations. The FactSet consensus target of $8.83 suggests some analysts assign more CVR value than the current $0.50 premium reflects. Deutsche Bank cut its target from $12 to $8, citing deal structure rather than pipeline concerns.
Why did AtaiBeckley insiders sell below deal price?
Three executives sold shares between June 25 and July 7 at prices ranging from $4.51 to $5.00, settling $1.75 to $2.24 per share below the Lilly acquisition price. This does not imply wrongdoing, as executives sell for personal reasons, but the gap suggests the deal terms surprised even those closest to the pipeline's development.
What does AtaiBeckley's pipeline include?
The pipeline includes BPL-003, an intranasal mebufotenin formulation in Phase 2a and 2b for treatment-resistant depression and alcohol use disorder, an oral MDMA analog for social anxiety, and a DMT film alongside a pro-cognitive neuromodulator for schizophrenia-related impairment. The company has 99 employees, no commercial products, and $230 million in cash with zero debt.
AtaiBeckley posted its first earnings beat in at least four quarters just days after Deutsche Bank stripped its Buy rating on the stock — citing the very Eli Lilly acquisition that shareholders are counting on for upside. With shares already trading above the $6.75 cash acquisition price, investors are now betting on contingent value rights that Wall Street is not fully crediting.